Quantum-Si Inc., a Branford-based biotech company, has announced a $50 million registered direct offering of common stock.
Quantum-Si Inc., a Branford-based biotech company, has announced a $50 million registered direct offering of common stock.
The company said it has entered into a securities purchase agreement with a single institutional investor, selling 29,940,119 shares of common stock and equivalents at $1.67 per share.
The transaction is expected to close on July 8, 2025, pending customary closing conditions.
Quantum-Si said it plans to use the net proceeds from the offering for “working capital and general corporate purposes.”
The offering is being conducted under an effective shelf registration statement previously declared effective by the U.S. Securities and Exchange Commission in August 2023.
Quantum-Si is a proteomics technology company that specializes in single-molecule protein analysis.
In January, Quantum-Si
raised $50 million in a registered direct offering of its Class A common stock.
Quantum-Si’s capital raising follows its
recent effort to regain compliance for listing its stock on The Nasdaq Stock Market.
Quantum-Si went public in June 2021, merging with New York-based HighCape Capital Acquisition Corp. in a deal worth $1.46 billion.
In 2022, Quantum-Si made its technology, powered by a semiconductor chip, commercially available.
On Tuesday morning, Quantum-Si's stock was trading at $1.80 per share, up about 0.5%.
